Terje Kalland

Terje Kalland is currently a Director at Accuro Immunology AB, Akinion Pharmaceuticals AB, Arts Biologics A, and a Member of the Royal Swedish Academy of Engineering Sciences.
Previously, he held positions such as Chief Executive Officer at Karolinska Development AB (Private Equity), Deputy CEO & Chief Scientific Officer at Karolinska Development AB, Chairman at KDev Oncology AB, Director at Dako Denmark ApS, Director at CBio Ltd., Director at KDev Exploratory AB, Deputy Director at Aprea Therapeutics AB, Director at Axelar AB, Director at ClanoTech AB, Director at Modus Therapeutics AB, Senior Vice President-Biopharmaceuticals Research at Novo Nordisk A, Head-Research & Development at Biovitrum AB, Head-Global Oncology Research at Pharmacia Corp., Member-Supervisory Board at Innate Pharma SA, and Professor at the University of Lund.
His current jobs include Director positions at Accuro Immunology AB, Akinion Pharmaceuticals AB, Arts Biologics A, and membership in the Royal Swedish Academy of Engineering Sciences.